Methylergonovine Maleate
NDC 43386-140
Product Information
Methylergonovine Maleate is a ANDA-approved product labeled by Lupin Pharmaceuticals,inc.. This medication is used after childbirth to help stop bleeding from the uterus. It is supplied as a white product. This product entry covers the primary NDC 43386-140 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
N;01
Code Structure Chart
Product Details
What is NDC 43386-140?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- METHYLERGONOVINE MALEATE (UNII: IR84JPZ1RK)
- METHYLERGONOVINE (UNII: W53L6FE61V) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONE K30 (UNII: U725QWY32X)
- STARCH, CORN (UNII: O8232NY3SJ)
- GELATIN (UNII: 2G86QN327L)
- ACACIA (UNII: 5C5403N26O)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- TARTARIC ACID (UNII: W4888I119H)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 996824 - methylergonovine maleate 0.2 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.
Patient Education
Methylergonovine
Methylergonovine belongs to a class of drugs called ergot alkaloids. Methylergonovine is used to prevent or treat bleeding from the uterus that can happen after childbirth or an abortion. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
[Learn More]
* Please review the full disclaimer at the bottom of this page.